NO reduction is a marker of the development of endothelial dysfunction in patients with CKD, which is caused by multiple factors, such as increased levels of endogenous inhibitors of endothelial NO synthase, advanced glycosylation products, phosphate, pro-inflammatory cytokines, oxidative stress, and fibroblast growth factor 23. This evidence concerns the gene FGF23 and endothelial dysfunction.